<scp>microRNA</scp>‐based diagnostic and therapeutic applications in cancer medicine
-
- Lorenzo F. Sempere
- Department of Radiology, Precision Health Program Michigan State University East Lansing Michigan USA
-
- Asfar S. Azmi
- Department of Oncology Wayne State University School of Medicine Detroit Michigan USA
-
- Anna Moore
- Departments of Radiology and Physiology, Precision Health Program Michigan State University East Lansing Michigan USA
説明
<jats:title>Abstract</jats:title><jats:p>It has been almost two decades since the first link between microRNAs and cancer was established. In the ensuing years, this abundant class of short noncoding regulatory RNAs has been studied in virtually all cancer types. This tremendously large body of research has generated innovative technological advances for detection of microRNAs in tissue and bodily fluids, identified the diagnostic, prognostic, and/or predictive value of individual microRNAs or microRNA signatures as potential biomarkers for patient management, shed light on regulatory mechanisms of RNA–RNA interactions that modulate gene expression, uncovered cell‐autonomous and cell‐to‐cell communication roles of specific microRNAs, and developed a battery of viral and nonviral delivery approaches for therapeutic intervention. Despite these intense and prolific research efforts in preclinical and clinical settings, there are a limited number of microRNA‐based applications that have been incorporated into clinical practice. We review recent literature and ongoing clinical trials that highlight most promising approaches and standing challenges to translate these findings into viable microRNA‐based clinical tools for cancer medicine.</jats:p><jats:p>This article is categorized under:<jats:list list-type="simple"> <jats:list-item><jats:p>RNA in Disease and Development > RNA in Disease</jats:p></jats:list-item> </jats:list></jats:p>
収録刊行物
-
- WIREs RNA
-
WIREs RNA 12 (6), e1662-, 2021-05-17
Wiley